Study on the neuroprotective effects of the Multiwave Locked System Laser in an experimental model of ischaemia

20 April 2022 - Research -
Share

The collaboration between a group of researchers from the University of Florence and ASAcampus Joint Laboratory has led to a wide-ranging research on the neuroprotective effects of the Multiwave Locked System Laser developed by ASA in ischaemia.
A well-established model of an in vitro cerebral ischaemia was used for this research: i.e. the deprivation of oxygen and glucose (Oxygen Glucose Deprivation; OGD) on organotypic cultures of rat hippocampus, a brain structure implicated in memory. The organotypic slices are obtained from hippocampal sections taken from 7-day-old new-born rats and kept in culture for two weeks. These slices preserve and reproduce the cytoarchitecture and physiology of the hippocampal tissue, an organ that is among the first to be affected by the ischemic insult.
The exposure of the slices to OGD for 30 minutes leads to the selective death of the pyramidal neurons of the CA1 region of the hippocampus, seen 24 hours after the ischemic insult.

The neuronal damage caused by the OGD and the neuroprotective effect of the laser were measured qualitatively and quantitatively thanks to immunohistochemical techniques associated with confocal laser microscopy in collaboration with the IFAC Institute of the Florence CNR.

Research focused on changes affecting microglia cells, the brain's resident immune system.

It has been shown that OGD causes a significant increase in a particular form of microglia involved in the phagocytosis of neurons damaged by ischaemia, called "Rod Microglia".
The results obtained are very interesting. In fact, the application of the laser on the organotypic slices not only significantly protects the neurons damaged by OGD, but also prevents the appearance of Rod microglia.

This study lays the foundations for many research perspectives in the field of photobiomodulation using near infrared laser radiation (NIR) and demonstrates the effectiveness of MLS® and its MiS device against ischemic damage in the brain. The study, which was recently published in the "International Journal of Molecular Sciences", confirms and extends the results obtained by a first research already published in 2021 (Molecular Neurobiology).

Testo a Destra
Immagine 30%/Testo 60%
International Journal of Molecular Sciences

“Hypoxia/Ischemia-Induced Rod Microglia Phenotype in CA1 Hippocampal Slices”
International Journal of Molecular Sciences, 23(3), 1422, 2022

READ MORE

Testo a Destra
Immagine 30%/Testo 60%

“NIR Laser Photobiomodulation Induces Neuroprotection in an In Vitro Model of Cerebral Hypoxia/Ischemia”
Molecular Neurobiology, 2021

READ MORE

You might also be interested in ...

See all articles

Supportive Care in Cancer - Springer
blog - 04/04/2022
The clinical trial investigated the efficacy and safety of photobiomodulation therapy (PBMT) delivered by laser source (M6) in the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in...
blog - 15/09/2021
The results of this study allow defining the neuroprotective mechanisms of the laser therapy carried out by MLS-MiS, to highlight its anti-inflammatory effect and to underline its potential benefit...
Effect of NIR Laser Therapy by MLS‐MiS Source on Fibroblast Activation by Inflammatory Cytokines in Relation to Wound Healing
blog - 12/04/2021
The ASA device have an important anti-inflammatory effect, but it is also effective in controlling fibroblast activation induced by IL‐1β and TNF‐α, probably responsible for a detrimental effect on...
ASA Partners Meeting 2024
News - 21/03/2024
Four days of full immersion in the world of ASA to focus on the new devices - M-Hi and HIRO – and to analyse the biological effects of Hilterapia®.
ASAlaser @ FIF Milano 2024
News - 19/03/2024
Not only top-of-the-line devices, including the new HIRO and M-Hi as well as Magneto Qs and M8, but also three workshops aimed at highlighting the strengths of its therapies.
ASA tema @ ArabHealth 2024
News - 15/02/2024
In order to provide maximum visibility and the best dissemination of the strengths of its Therapeutic Solutions, the company preceded its attendance at the fair (Dubai, 29th January – 1st February)...